LIPOSYN III 30%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIPOSYN III 30% (LIPOSYN III 30%).
Liposyn III 30% is a lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories for parenteral nutrition. It serves as a substrate for energy production and component of cell membranes.
| Metabolism | Metabolized by lipoprotein lipase in peripheral tissues; hydrolyzed to free fatty acids and glycerol. Free fatty acids undergo beta-oxidation or re-esterification. |
| Excretion | Liposyn III 30% is a fat emulsion; its components are metabolized like endogenous triglycerides. Clearance involves hydrolysis by lipoprotein lipase, releasing free fatty acids which are oxidized or stored. Less than 1% is excreted unchanged in urine; a small fraction is excreted in bile/feces. No significant renal or biliary elimination of intact emulsion. |
| Half-life | The terminal elimination half-life of the triglyceride component is approximately 30 minutes (range 20-40 minutes) in patients with normal lipid metabolism. In critically ill patients or those with impaired clearance, half-life may be prolonged. |
| Protein binding | The fatty acids released from the emulsion are highly bound to albumin (>99%). Intact emulsion particles do not significantly bind to plasma proteins. |
| Volume of Distribution | Vd is approximately 0.09-0.15 L/kg, indicating confinement to the vascular space. The emulsion particles are distributed within plasma volume. |
| Bioavailability | Intravenous administration results in 100% bioavailability. |
| Onset of Action | Intravenous infusion: Maximum plasma triglyceride concentration is reached within 1-2 hours of initiating infusion. Clinical effect (caloric provision) occurs during infusion. |
| Duration of Action | The metabolic effects persist for the duration of the infusion plus several hours after discontinuation. After a single dose, plasma triglycerides return to baseline within 4-6 hours. Prolonged infusions may lead to sustained lipid clearance. |
Adults: 1-2 g/kg/day intravenously, not to exceed 2.5 g/kg/day. Initial rate 0.5-1 mL/min for first 30 minutes, increase to 100-125 mL/h as tolerated.
| Dosage form | INJECTABLE |
| Renal impairment | GFR < 30 mL/min: Reduce dose by 50% and monitor triglycerides. GFR < 15 mL/min: Consider alternative therapy or reduce dose further. Not recommended in dialysis. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25-50% and monitor triglycerides. Child-Pugh C: Contraindicated or use extreme caution with severe dose reduction. |
| Pediatric use | Neonates and infants: 0.5-1 g/kg/day, increase by 0.5 g/kg/day increments up to 3 g/kg/day (max). Children: 1-2 g/kg/day, infuse over 24 hours. Rate not to exceed 0.1 g/kg/h. |
| Geriatric use | Start at lower end of adult dose (1 g/kg/day) and titrate based on tolerance, renal function, and triglyceride levels. Monitor for fluid overload and hypertriglyceridemia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LIPOSYN III 30% (LIPOSYN III 30%).
| Breastfeeding | It is not known whether Liposyn III 30% or its components are excreted in human milk. Because many drugs and nutrients are excreted in breast milk, caution should be exercised when administered to a nursing woman. No M/P ratio is available. The product is a fat emulsion; endogenous fats are normally present in breast milk. There is theoretical concern for chylomicronemia or alteration of milk composition, but data are lacking. Use during lactation is generally reserved for clear maternal indication. |
| Teratogenic Risk | Liposyn III 30% is an intravenous fat emulsion consisting of soybean oil, egg yolk phospholipids, glycerin, and water. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. In clinical practice, use in pregnancy is generally avoided unless clearly needed, especially during the first trimester. However, as a source of essential fatty acids and calories, it may be used in pregnant women requiring parenteral nutrition. Potential risks include metabolic acidosis, hypertriglyceridemia, and fat overload syndrome, which could affect fetal well-being indirectly. The risk of teratogenicity is considered low but not definitively established. |
■ FDA Black Box Warning
Death in preterm infants: Use of lipid emulsions in preterm infants has been associated with increased risk of death, particularly those with pre-existing lung disease. Use only when clearly indicated and with caution.
| Serious Effects |
["Severe hyperlipidemia or lipoid nephrosis","Acute pancreatitis with hyperlipidemia","Pathologic hyperlipidemia","Severe egg or soybean allergy (contains egg phospholipids and soybean oil)","Kernicterus in neonates due to bilirubin displacement"]
| Precautions | ["Risk of fat overload syndrome (hepatomegaly, fever, jaundice, coagulation abnormalities) with rapid infusion or renal impairment.","Monitor serum triglycerides regularly; discontinue if levels exceed 400 mg/dL.","Use with caution in patients with severe hepatic damage, pulmonary disease, anemia, or coagulopathies.","May cause intravenous fat emulsion-induced acute lung injury."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum triglycerides, liver function tests, coagulation parameters, and complete blood count regularly during infusion. Assess for signs of fat overload syndrome (e.g., hepatomegaly, splenomegaly, thrombocytopenia, coagulopathy). Monitor fetal heart rate and uterine activity if used in late pregnancy. Assess maternal metabolic status, including glucose and electrolytes. In preterm or low-birth-weight infants, monitor for hypertriglyceridemia if transplacental transfer occurs near delivery. |
| Fertility Effects | No human data on fertility effects. Animal studies have not been reported. As a caloric substrate, severe malnutrition may impair fertility, but Liposyn III 30% itself is not expected to affect fertility when used appropriately. |